BY MIKKEL AABENHUS HEMMINGSEN社区股东
-
Boehringer Ingelheim stops development of Gubra obesity drug
Gubra has actually not gotten any type of additional details regarding the choice.
-
Berenberg expects Eli Lilly to continue strong momentum in obesity market
The German financial institution restates its “acquire” referral on Eli Lilly in advance of the pharmaceutical firm’s monetary outcomes.
-
Viking Therapeutics close to phase 2 start with weight loss tablet
The tablet computer can end up being a day-to-day option to an once a week subcutaneous formula likewise being created by the United States business.
-
Roche recommends blocking Novo’s acquisition of Catalent
Prior to now, US shopper teams and labor unions have additionally requested the US Commerce Fee to dam the acquisition.
-
Lundbeck writes down drug candidate by USD 79 million
A stage 1 test has actually disappointed the wanted outcomes.
-
Novo Holdings leads Series B round in cell therapy company
The firm was started in 2021 by Blackstone Life Sciences, Cellex Cell Professionals and Intellia Rehabs.
-
Europe continues to lose ground in clinical trials
The European share is now simply 9%, in comparison with 19% ten years in the past.
-
CHMP recommends ten new medicines
The company likewise suggests added applications for one more 6 medications.
-
FDA grants Breakthrough Therapy Designation to Boehringer Ingelheim’s survodutide
Boehringer Ingelheim has actually likewise introduced 2 stage III tests for survodutide to additionally explore the medication’s performance.
-
Fish skin from Coloplast acquisition effective as diabetic foot ulcer treatment
Diabetic foot abscess can be tough to deal with and can result in infection and also amputation otherwise appropriately dealt with.